Key result
Long-acting nitric oxide donors may treat VEGF inhibitor-induced hypertension driven by decreased nitric oxide.
Population
Cancer patients developing hypertension due to vascular endothelial growth factor pathway inhibitors therapy
Design
Review
Authors
Loading...
Long-acting nitric oxide donors merit trial evaluation for VEGF inhibitor-induced hypertension; hypothesis-generating and should not yet change practice.
This review suggests a potential treatment procedure based on long-acting nitric oxide donors for managing hypertension induced by VEGF pathway inhibitors in cancer patients.
Kružliak et al. (2013) conducted a review in Vascular endothelial growth factor inhibitor-induced hypertension. Long-acting nitric oxide donors was evaluated. Vascular endothelial growth factor inhibitor-induced hypertension is driven by decreased nitric oxide, prompting the suggestion of long-acting nitric oxide donors as a potential treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: